NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Urothelial Carcinoma, Carcinoma, Non-Small Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Carcinoma, Hepatocellular Carcinoma

Interventions: Atezolizumab

Countries: South Korea

This Phase 4, prospective, multicenter, non-interventional, regulatory post-marketing surveillance study will collect information on the the safety and effectiveness of atezolizumab under the clinical practice, and update the drug label approved by the MFDS in Korea.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Participants who are administered with atezolizumab for the locally approved indications

Exclusion Criteria:

* Participants with a known hypersensitivity to atezolizumab or to any of the excipients

Locations (56)

Busan, South Korea
Busan, South Korea
Busan, South Korea
Busan, South Korea
Busan, South Korea
Busan, South Korea
Busan, South Korea
Busan, South Korea
Busan, South Korea
Daegu, South Korea
Daegu, South Korea
Daegu, South Korea
Daegu, South Korea
Daejeon, South Korea
Gangwon-do, South Korea
Gangwon-do, South Korea
Gangwon-do, South Korea
Gyeonggi-do, South Korea
Gyeonggi-do, South Korea
Gyeonggi-do, South Korea
Gyeonggi-do, South Korea
Gyeonggi-do, South Korea
Gyeonggi-do, South Korea
Gyeonggi-do, South Korea
Gyeongsangnam-do, South Korea
Hwaseong-si, South Korea
Jeollabuk-do, South Korea
Jeollanam-do, South Korea
Jeonlabuk-do, South Korea
Seoul, South Korea
+ 26 more on CT.gov